Novo says its next-gen obesity drug tops Lilly rival in late-stage study
LLY•Late-stage obesity trial results
Sept. 21 (Reuters) - Novo Nordisk said on Monday its next-generation experimental drug had achieved an estimated average weight loss of 12.4% in a late-stage trial and that it was superior to Eli Lilly's drug.
